Jump to content
RemedySpot.com

Have You Been Fooled by These Dirty Pharma Tricks?

Rate this topic


Recommended Posts

Posted

http://www.foodconsumer.org/newsite/Non-food/Drug/dirty_pharma_tricks_1226101236.html

Have You Been Fooled by These Dirty Pharma Tricks?

12/26/2010 18:34:00

By Martha Rosenberg

How does the pharmaceutical industry get a product through

development, testing and approval and onto your insurer's

formulary, television set and bathroom shelf? (And Wall Street

profit reports?) And how does it do it so, so seamlessly you think

it's your idea? Here are some of pharma's dirtiest tricks.

Playing the Price Spread

In drug sales, the price pharmacies pay and the

government reimburses are not the same. This lets pharma inflate

government's Average Wholesale Price (AWP) and play the spread

either for kickbacks or sales "incentives." Exploiting the price

difference is so common, AWP could stand for Ain't What's Paid

says Tony West, assistant attorney general for the Justice

Department's civil division, because "the only purchasers who paid

the inflated, reported drug price were you, the American

taxpayers." Maybe the classic claim "I got it wholesale" isn't so

good after all.

Double dealing at the Pharmacy

Why did pharma send letters to doctors through CVS pharmacy

extolling the expensive drug Zyprexa? Even though CVS' pharmacy

benefit manager, AdvancePCS, is pledged to negotiate the lowest

drug prices for its insurer and pensions plan clients? Because

pharmacy benefit managers (PBMs) increasingly play both side of

the street, says the Boston Globe. The extra $3,000 to $9,000 per

person per year that Zyprexa costs over a generic will do a lot

for Lilly stock. If you don't think about health insurance

premiums.

Faux Patient Groups

Ever wonder how patient groups lobbying FDA to approve some

expensive drug you've never heard of suddenly appear? Replete with

tears and sob stories? The patient front groups, sometimes called

astroturf, are aggregated and orchestrated by pharma. One of the

largest, the "grassroots" National Alliance on Mental Illness

(NAMI), lobbies Medicaid programs not to substitute less expensive

drugs and was investigated by Sen. Grassley for

undisclosed pharma links. How can you tell an astroturf group? Its

web site looks just like pharma's.

FDA Foreplay

Sometimes when pharma thinks it is sitting on a revolutionary

drug, it doesn't wait for FDA approval and begins marketing

directly to the public. A recent example was a drug to treat

female sexual dysfunction and hopefully be a blockbuster like

Viagra. What was not to like? Who could say no? But after

Boehringer-Ingelheim debuted its pink Viagra for "hypoactive

sexual desire disorder" (HSDD) at a medical conference last year

and rolled out its elaborate Sex Brain Body: Make the Connection

web site and campaign starring TV personality Rinna, FDA did

say no. Seems even though Boehringer-Ingelheim was effective in

"raising awareness" about female sexual dysfunction, something

else wasn't effective: the drug.

Pharma Service Announcements

Like ghostwriting, the origins of pharma's unbranded advertising

are disguised and they look legit. But when TV, radio and web

messages push "awareness" of diseases like ADHD, Irritable Bowel

Syndrome (IBS), Restless Legs Syndrome (RLS) or Excessive

Sleepiness (ES), be suspicious. Real diseases aren't given

initials for quick recall and easy reference. Nor do they come

with snappy self-quizzes and pretty patient models. Unbranded

messages also pimp the PSA (public service announcement) money

that media outlets have for actual public issues.

National "Interests of Health

The billions of research dollars the taxpayer-supported National

Institutes of Health (NIH) allocates each year are supposed to

benefit the public and be free from pharma influence. So why was a

researcher stripped of an NIH grant because of hidden pharma ties,

allowed to resume NIH funding at a new university? Psychiatrist

Nemeroff not only qualified for NIH funds when he surfaced

at the University of Miami last year, he sits on the actual NIH

committees which consider other researchers 'grants, reports

Chronicle of Higher Education. A fox guarding the hen, or pork

house.

Continuing Marketing Education

Pharma-subsidized Continuing Medical Education (CME) courses are

a bonanza for pharma since doctors need the "credits" to keep

their licenses. But what are they learning? A recent "course"

offered by Medscape titled Quadrivalent HPV Vaccine May Be

Effective in Women 24 to 45 Years Old told participants after

taking the course, they would be able to "specify the currently

recommended age range" for the vaccine. Especially if they could

read the title! Another course offered by the Cleveland Clinic

Journal of Medicine tells participates to "lobby your legislators"

for pharma-related Medicare funding. No wonder, Congress recently

investigated the billion dollar industry CME industry for illegal

marketing. Too bad it couldn't investigate for stupidity.

Ghostwriting and Nolo Retracto

Ghostwriting -- papers written by medical marketing writers with

doctors only posing as authors -- was rampant until 2008

Congressional investigations. But even though it's now

prohibited, few journals have retracted ghostwritten articles

which sold Vioxx, Fen Phen, Prempro and probably Avandia. Asked

about the ghostwritten papers "by" Lila Nachtigall, a professor in

the Department of Obstetrics and Gynecology, Deborah Bohren, vice

president for public affairs at New York University's Langone

Medical Center said, "If we had received a complaint, we would

have investigated." A Congressional investigation doesn't qualify

as a complaint?

Crooked Books and Slanted Messages

First it was called the first completely ghostwritten book. Then

it was called a completely pharma approved book. Either way, the

1999 textbook, Recognition and Treatment of Psychiatric Disorders:

A Psychopharmacology Handbook for Primary Care, was funded by an

"unrestricted educational grant" from drug giant GlaxoKline

(GSK) to Scientific Therapeutics Information according to its own

preface. Nor were its authors strangers to GSK. Alan Schatzberg is

on GSK's speakers bureau and Nemeroff was investigated by

Congress for undeclared GSK income. Did the authors write the book

themselves or was it ghostwritten by freelancers at Scientific

Therapeutics Information (the group that marketed Vioxx?) Does it

matter?

May I Take Your Order?

Have you ever waited in a doctor's office with a 102 degree fever

only to have pharma reps swinging Vytorin totes see the doctor

first? Just because they brought free samples or lunch and are

dressed for a music video? Until Congressional investigations into

physician payments culminating in the Physician Payments Sunshine

Act, some doctors in medical centers say they never paid for a

meal. Nor did pharma largesse end there. One doctor told a

reporter her entire group were jetted to a Caribbean island

courtesy of her Paxil rep. Even medical students were schmoozed

until the 62,000 member American Medical Student Association

(AMSA) sought to end the pharma practice of gifts and free meals.

Now pharma must report what it spends on doctors...and there is a

longer line at the vending machine.

Trials and Fibulations

Would researchers really compromise patient safety to make a buck

with clinical trials? Medical College of Georgia psychiatrist

Borison and his colleague Bruce Diamond did 13 years ago

when they tested Zyprexa, Risperdal and 20 other drugs and ended

up in jail. So did Baystate Medical Center's Reuben who went

to prison earlier this year for fraudulent Celebrex, Neurontin

and Lyrica trials. And a Tucson facility testing asthma drugs

Symbicort, Advair and Singulair doctored data and risked patients'

health to net as much as $10,000 per patient according to a

whistleblower and government and court documents. How many other

drugs were tested for such fiscal outcomes? Not counting recalled

ones of course.

More Trials and Fibulations

Even without fraud, pharma sponsored studies can deceive. Trials

that only determine that a drug is "not worse" than another one or

impute safety before real data -- like Vioxx and Avandia's heart

attacks -- are available can skew results. And some research is

not meant to be accurate to begin with. The &

Center for Pediatric Psychopathology

Research at Massachusetts General Hospital was founded to "move

forward the commercial goals of J. & J." according to unsealed

court documents. Its head, Harvard's ph Biederman, promised

J. & J. a proposed drug trial "will support the safety and

effectiveness of risperidone [Risperdal] in this age group,"

before it was ever conducted. Why leave things up to science?

Overseas Adventurism

As pharma increasingly eyes poorer countries for new markets and

cheaper manufacturing it also eyes them for cheaper clinical

trials. In 1996, 11 Nigerian children died in trials testing

Pfizer's not-yet-approved antibiotic Trovan. While Pfizer paid the

Nigerian government and state of Kano millions in a settlement,

Wikileaks reports that Pfizer tried to extort Nigeria's former

attorney general to drop the lawsuits. Trovan was withdrawn from

US markets in 2001 for liver toxicity but it sounds like "safety

signals" may have appeared sooner.

Clueless Institutional Review Boards

Institutional review boards, charged with overseeing clinical

trials, should catch the Borisons, Trovans and preordained

Biederman trials. But a Congress and General Accountability Office

sting conducted last year on a Colorado IRB raises serious doubts.

When asked to oversee a study of Adhesiabloc, a product designed

to reduce scar tissue that didn't exist (nor did its developer or

lead researcher) Coast Independent Review Board said...when do we

start?

"Previous Government Experience Desirable"

In the fight against medical fraud, the Justice Department is

beginning to file criminal, not just civil, charges against

pharma. More employees also are turning whistleblower thanks to

provisions that entitle whistleblowers to 15 and even 30 percent

of fraud settlement, in some cases. But the other side has a big

advantage. As long as politicians like former Louisiana Rep.

Tauzin, who left government to head the industry trade group

PhRMA, and former CDC director Gerberding, now head of Merck

vaccines, are willing to commit a career's worth of knowledge,

judgment and relationships to sell product, the government is

fighting itself.

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...